公开(公告)号：EP1194421B1

公开(公告)日：2005-10-12

申请号：EP00923603.5

申请日：2000-04-21

申请人： H. LUNDBECK A/S ,  Novartis AG

发明人： MARZABADI, Mohammad, R. ,  WONG, Wai, C. ,  NOBLE, Stewart, A. ,  BUHLMAYER, Peter ,  RUEGER, Heinrich ,  YAMAGUCHI, Yasuchika ,  SCHILLING, Walter

IPC分类号： C07D277/60 ,  A61K31/426 ,  A61K31/428 ,  C07D277/42 ,  C07D417/12 ,  C07D513/04 ,  A61K31/429

CPC分类号： C07D277/60 ,  C07D277/42 ,  C07D417/12 ,  C07D513/04

摘要： This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.